ALIM · Alimera Sciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.00M | $23.01M | - | $23.36M | $17.54M | $13.55M | - | $13.60M | $14.60M | $11.90M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $23.17M | $19.66M | - | $20.61M | $15.11M | $11.52M | - | $11.59M | $12.44M | $10.22M |
| R&D | $4.26M | $4.36M | - | $4.04M | $3.65M | $4.16M | - | $4.48M | $3.93M | $3.58M |
| SG&A | $7.38M | $5.43M | - | $3.61M | $4.37M | $4.17M | - | $3.35M | $2.94M | $3.24M |
| Total Operating Expenses | $23.25M | $21.96M | - | $18.75M | $16.32M | $14.82M | - | $15.00M | $14.41M | $14.37M |
| D&A | $1.87M | $3.08M | - | - | - | $681.0K | - | - | - | $689.0K |
| Operating Income | ($77.0K) | ($2.30M) | - | $1.85M | ($1.21M) | ($3.30M) | - | ($3.41M) | ($1.97M) | ($4.15M) |
| Interest Expense | $3.15M | $3.74M | - | $2.07M | $1.69M | $1.67M | - | $1.50M | $1.38M | $1.36M |
| Income Tax | ($43.0K) | ($32.0K) | - | $53.0K | $25.0K | - | - | $12.0K | $17.0K | - |
| Net Income | ($3.31M) | ($6.25M) | - | ($1.35M) | ($10.03M) | ($4.97M) | - | ($5.26M) | ($3.12M) | ($5.96M) |
| EPS - Basic | ($0.06) | ($0.12) | - | ($0.06) | ($1.32) | ($0.71) | - | ($0.60) | ($0.45) | - |
| EPS - Diluted | - | ($0.12) | - | ($0.06) | ($1.32) | ($0.71) | - | ($0.60) | ($0.45) | - |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.83M | $14.31M | $12.06M | $8.29M | $18.77M | $13.09M | $5.27M | $5.51M | $7.86M | $9.95M |
| Accounts Receivable | $37.08M | $34.22M | $34.55M | $33.94M | $22.59M | $18.43M | $19.61M | $19.14M | $20.32M | $18.78M |
| Inventory | $3.46M | $2.21M | $1.88M | $1.76M | $1.05M | $1.22M | $1.60M | $1.79M | $1.66M | $2.45M |
| Accounts Payable | $10.21M | $10.31M | $8.25M | $6.21M | $8.04M | $9.67M | $10.09M | $8.71M | $7.61M | $6.60M |
| Current Assets | $55.41M | $54.47M | $52.42M | $48.40M | $46.02M | $35.67M | $29.41M | $29.76M | $33.07M | $34.75M |
| Total Assets | $150.38M | $152.49M | $153.52M | $154.19M | $154.92M | $48.24M | $42.60M | $43.43M | $47.57M | $49.93M |
| Current Liabilities | $19.84M | $20.79M | $21.91M | $17.72M | $14.24M | $14.17M | $39.73M | $34.01M | $25.43M | $17.01M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $111.59M | $111.83M | $107.35M | - | - | - | $63.41M | - | - | - |
| Stockholders' Equity | $38.79M | $40.65M | $46.17M | $48.84M | $46.23M | ($18.92M) | ($20.81M) | ($18.08M) | ($12.34M) | ($8.60M) |
| Retained Earnings | ($428.05M) | ($424.74M) | ($418.49M) | ($414.71M) | ($412.78M) | ($402.08M) | ($415.39M) | ($411.61M) | ($406.35M) | ($403.24M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($566.0K) | - | - | - | ($2.21M) | - | - | - | ($6.21M) |
| Investing Cash Flow | - | ($21.0K) | - | - | - | ($9.0K) | - | - | - | ($149.0K) |
| Financing Cash Flow | - | $2.97M | - | - | - | $10.00M | - | - | - | ($62.0K) |
| CapEx | - | $21.0K | - | - | - | $9.0K | - | - | - | $149.0K |
| Free Cash Flow | - | ($587.0K) | - | - | - | ($2.22M) | - | - | - | ($6.36M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 85.8% | 85.4% | - | 88.2% | 86.2% | 85.0% | - | 85.2% | 85.2% | 85.9% |
| Operating margin | -0.3% | -10.0% | - | 7.9% | -6.9% | -24.4% | - | -25.1% | -13.5% | -34.9% |
| EBITDA margin | 6.6% | 3.4% | - | - | - | -19.3% | - | - | - | -29.1% |
| Net margin | -12.3% | -27.2% | - | -5.8% | -57.2% | -36.7% | - | -38.7% | -21.3% | -50.1% |
| Free cash flow margin | - | -2.6% | - | - | - | -16.4% | - | - | - | -53.5% |
| FCF / Net income | - | 0.09 | - | - | - | 0.45 | - | - | - | 1.07 |
| R&D / Revenue | 15.8% | 19.0% | - | 17.3% | 20.8% | 30.7% | - | 33.0% | 26.9% | 30.1% |
| SG&A / Revenue | 27.3% | 23.6% | - | 15.4% | 24.9% | 30.8% | - | 24.7% | 20.2% | 27.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.2% | -4.1% | - | -0.9% | -6.5% | -10.3% | - | -12.1% | -6.5% | -11.9% |
| Return on equity | -8.5% | -15.4% | - | -2.8% | -21.7% | 26.3% | - | 29.1% | 25.3% | 69.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.79 | 2.62 | 2.39 | 2.73 | 3.23 | 2.52 | 0.74 | 0.88 | 1.30 | 2.04 |
| Quick ratio | 2.62 | 2.51 | 2.31 | 2.63 | 3.16 | 2.43 | 0.70 | 0.82 | 1.24 | 1.90 |
| Cash ratio | 0.55 | 0.69 | 0.55 | 0.47 | 1.32 | 0.92 | 0.13 | 0.16 | 0.31 | 0.58 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.0x | -0.6x | - | 0.9x | -0.7x | -2.0x | - | -2.3x | -1.4x | -3.0x |
| Equity multiplier | 3.88 | 3.75 | 3.33 | 3.16 | 3.35 | -2.55 | -2.05 | -2.40 | -3.86 | -5.80 |
| Liabilities / Assets | 0.74 | 0.73 | 0.70 | - | - | - | 1.49 | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.18 | 0.15 | - | 0.15 | 0.11 | 0.28 | - | 0.31 | 0.31 | 0.24 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 501d | 543d | - | 530d | 470d | 497d | - | 514d | 508d | 576d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 54.0% | 69.9% | - | 71.8% | 20.1% | 13.9% | - | 11.9% | -32.7% | 6.1% |
| Revenue CAGR (3y) | 7.6% | 27.1% | - | 23.3% | 20.4% | -2.3% | - | 1.9% | 10.4% | 7.3% |
| Revenue CAGR (5y) | 20.0% | 19.0% | - | 19.0% | 9.9% | 6.7% | - | 6.8% | 7.1% | 12.4% |
| Gross profit growth (YoY) | 53.3% | 70.7% | - | 77.8% | 21.5% | 12.7% | - | 10.8% | -37.5% | 5.9% |
| Operating income growth (YoY) | 93.6% | 30.3% | - | - | 38.8% | 20.4% | - | -68.7% | - | -70.7% |
| Net income growth (YoY) | 67.0% | -25.8% | - | 74.2% | -222.0% | 16.6% | - | -25.7% | - | -63.2% |
| EPS growth (YoY) | - | 83.1% | - | 90.0% | -193.3% | - | - | - | 11.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 73.5% | - | - | - | 65.1% | - | - | - | -146.1% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -16.1% | - | - | - | - | -119.9% | -698.8% | - | - | 28.1% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ALIMERA SCIENCES INC against the 5 most active filers in the same SIC group.